WEST Search History

DATE: Wednesday, October 23, 2002

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
L10	L4 and l1	2	L10
L9	L7 same (bone or osteo$ or meyloma)	11	L9
L8	L7 same (bone or osteo$)	11	L8
L7	L5 same (treat$ or vivo or administer$ or therap$)	246	L7
L6	L5 same (treat or vivo or administer$ or therap$)	195	L6
L5	L4 with (anti or antibod$)	376	L5
L4	((alpha.4.) or (alpha adj 4) or (alpha 4)or (vla adj 4) or vla 4 or vla-4)	5395	L4
L3	L2 and l1	6	L3
L2	yoneda-toshiyuki.in.	38	L2
L1	Mundy-gregory-$.in.	42	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:30:07 ON 23 OCT 2002)

INDEX '1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, EVENTLINE, HEALSAFE, IMSDRUGCONF, ISMEC, LIFESCI, OCEAN, MEDICONF, PASCAL, PAPERCHEM2, POLLUAB, SOLIDSTATE, ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, CANCERLIT, ...' ENTERED AT 12:30:41 ON 23 OCT 2002

SEA (ALPHA 4 OR (ALPHA (A) 4) OR (ALPHA.4.) OR ALPHA4 OR (VLA (

1	FILE 1MOBILITY
844	FILE AGRICOLA
141	FILE AQUASCI
3799	FILE BIOTECHNO
307	FILE COMPENDEX
4	FILE COMPUAB
128	FILE CONFSCI
13	FILE ELCOM
7	FILE HEALSAFE
8	FILE ISMEC
2904	FILE LIFESCI
33	FILE OCEAN
1	FILE MEDICONF
5389	FILE PASCAL
101	FILE PAPERCHEM2
18	FILE POLLUAB
46	FILE SOLIDSTATE
117	FILE ADISALERTS
70	FILE ADISINSIGHT
10	FILE ADISNEWS
10110	FILE BIOSIS
2083	FILE CANCERLIT
21869	FILE CAPLUS
9	FILE CEN
666	FILE DDFB
847	FILE DDFU
2088	FILE DGENE
666	FILE DRUGB
40	FILE DRUGNL
1167	FILE DRUGU
118	FILE EMBAL
9411	FILE EMBASE
3538	FILE ESBIOBASE
2155	FILE IFIPAT
59	FILE IPA
734	FILE JICST-EPLUS
11	FILE KOSMET
8392	FILE MEDLINE
1031	FILE NAPRALERT
185	FILE NLDB
21	FILE PHARMAML
51	FILE PHIN
9049	FILE SCISEARCH
5348	FILE TOXCENTER
15808	FILE USPATFULL
135	FILE USPAT2
206	FILE ANABSTR
323	FILE BIOBUSINESS
19	FILE BIOCOMMERCE
392	FILE BIOTECHABS
392	FILE BIOTECHDS
1558	FILE CABA
73	FILE CEABA-VTB
49	FILE CIN
41	FILE CROPB

```
              76   FILE CROPU
              61   FILE DRUGUPDATES
             139   FILE FEDRIP
               3   FILE FOREGE
              47   FILE FROSTI
             732   FILE FSTA
            2945   FILE GENBANK
              26   FILE NIOSHTIC
              86   FILE NTIS
              79   FILE PHAR
             239   FILE PROMT
              41   FILE SYNTHLINE
               8   FILE VETB
              21   FILE VETU
            1888   FILE WPIDS
            1888   FILE WPINDEX
L1              QUE (ALPHA 4 OR (ALPHA (A) 4) OR (ALPHA.4.) OR ALPHA4 OR (VLA (
                ---------

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, MEDLINE, PASCAL,
     TOXCENTER, BIOTECHNO, ESBIOBASE, GENBANK, LIFESCI, IFIPAT, DGENE,
     CANCERLIT, WPIDS, CABA, DRUGU, NAPRALERT, AGRICOLA, JICST-EPLUS, FSTA,
     DRUGB, BIOTECHDS, BIOBUSINESS, COMPENDEX, PROMT, ...' ENTERED AT 12:35:57
     ON 23 OCT 2002
L2           5234 S L1 (S) (ANTI OR ANTIBOD?) (S) (TREAT? OR ADMINISTER? OR THERA
L3            557 S L2 (S) (BONE OR OSTEO? OR MEYLOMA)
L4            434 S L3 (S) ((MULTIPLE (A) MEYLOMA) OR (BONE (A) RESORPTION) OR
L5           2080 S L1 (S) ((MULTIPLE (A) MEYLOMA) OR (BONE (A) RESORPTION) OR (B
L6            132 DUP REM L4 (302 DUPLICATES REMOVED)

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, IFIPAT, DGENE,
     CANCERLIT, WPIDS, CABA, DRUGU, BIOTECHDS, PROMT, NLDB, FEDRIP,
     ADISALERTS, ADISINSIGHT' ENTERED AT 13:14:30 ON 23 OCT 2002
L7            31 S L3 (S) ((MULTIPLE (A) MYELOMA) OR (BONE (A) RESORPTION))
L8            14 DUP REM L7 (17 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 13:19:04 ON 23 OCT 2002

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, WPIDS, NLDB' ENTERED
     AT 13:27:10 ON 23 OCT 2002
                E MUNDY GREGORY?/AU
L9            353 S E1 OR E2
                E YONEDA TOSHIYUKI?/AU
L10           156 S E2
L11            75 S L9 AND L10
L12             2 S L11 AND L6
```

WEST

Generate Collection | Print

39/943,659

L5: Entry 1 of 2 File: PGPB Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020041874
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020041874 A1

TITLE: Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mundy, Gregory R.	San Antonio	TX	US	
Yoneda, Toshiyuki	San Antonio	TX	US	

US-CL-CURRENT: 424/131.1; 424/133.1, 424/141.1, 424/178.1

CLAIMS:

1. A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

2. The method of claim 1, wherein the antagonist is an .alpha.4 integrin binding agent.

3. The method of claim 1, wherein the antagonist is an .alpha.4 integrin ligand binding agent.

4. The method of claim 2, wherein the .alpha.4 integrin binding agent is selected from the group consisting of: a) an antibody homolog that antagonizes the interaction of both VLA-4 and .alpha.4.beta.7 with their respective .alpha.4 ligands; b) an antibody homolog that antagonizes the interaction of VLA-4 with its .alpha.4 ligand; and c) an antibody homolog that antagonizes the interaction of .alpha.4.beta.7 with its .alpha.4 ligand.

5. The method of claim 4, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

6. The method of claim 3, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.

7. The method of claim 6, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

8. The method of claim 1, wherein the antagonist is a small molecule.

9. The method of claim 1, wherein said antagonist is an antagonist of VLA-4.

10. The method of claim 8, wherein said small molecule is: 3BIO-8809.

11. The method of claim 1, wherein the composition is administered at a dosage so as

to provide from about 0.1 to about 20 mg/kg body weight.

12. A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a first composition comprising an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin, wherein said first composition is administered in combination with a therapeutically effective amount of a second composition comprising a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

13. The method of claim 12, wherein said compound is a chemotherapeutic agent.

14. The method of claim 13, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

15. The method of claim 14, wherein said chemotherapeutic agent is melphalan.

16. The method of claim 12, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said second composition than not administered in combination with said second composition; or a dosage of said compound is lower when administered in combination with said first composition than not administered in combination with said second composition, or both.

17. A method for inhibiting bone resorption associated with tumors of bone marrow, the method comprising administering to a mammal with said tumors an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin, in an amount effective to provide inhibition of said bone resorption.

18. The method of claim 17, wherein the antagonist is an .alpha.4 integrin binding agent.

19. The method of claim 17, wherein the antagonist is an .alpha.4 integrin ligand binding agent.

20. The method of claim 17, wherein the .alpha.4 integrin binding agent is an anti-VLA4 antibody homolog or anti-.alpha.4.beta.7 antibody homolog.

21. The method of claim 20, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

22. The method of claim 19, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.

23. The method of claim 22, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

24. The method of claim 17, wherein the antagonist is a small molecule.

25. The method of claim 17, wherein said antagonist is an antagonist of VLA-4.

26. The method of claim 24, wherein said small molecule is: 4BIO-8809.

27. The method of claim 17, wherein the antagonist is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg, based on the weight of the individual.

28. The method of claim 24, wherein the antagonist is administered in an amount effective to provide a dosage of small molecule of about 0.1-30 mg/kg body weight.

29. The method of claim 17, wherein said antagonist is administered in combination

with a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

30. The method of claim 29, wherein said compound is a chemotherapeutic agent.

31. The method of claim 30, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

32. The method of claim 30, wherein said chemotherapeutic agent is melphalan.

33. The method of claim 29, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said compound than not administered in combination with said compound; or a dosage of said compound is lower when administered in combination with said antagonist than not administered in combination with said antagonist, or both.

34. A method of treating a subject having a disorder characterized by the presence of osteoclastogenesis, the method comprising administering to the subject an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit bearing integrin, in an amount sufficient to suppress the osteoclastogenesis.

35. The method of claim 34, wherein the antagonist is an .alpha.4 integrin binding agent.

36. The method of claim 34, wherein the antagonist is an .alpha.4 integrin ligand binding agent.

37. The method of claim 35, wherein the .alpha.4 integrin binding agent is an anti-VLA4 antibody homolog or an anti-.alpha.4.beta.7 binding agent.

38. The method of claim 36, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

39. The method of claim 36, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.

40. The method of claim 39, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

41. The method of claim 34 wherein the antagonist is a small molecule.

42. The method of claim 41, wherein said antagonist is an antagonist of VLA-4.

43. The method of claim 41, wherein said small molecule is: 5BIO-8809.

44. The method of claim 34, wherein the antagonist is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg body weight.

45. The method of claim 41, wherein the antagonist is administered in an amount effective to provide a dosage of small molecule of about 0.1-20 mg/kg body weight.

46. The method of claim 34, wherein said antagonist is administered in combination with a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

47. The method of claim 46, wherein said compound is a chemotherapeutic agent.

48. The method of claim 47, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

49. The method of claim 47, wherein said chemotherapeutic agent is melphalan.

50. The method of claim 46, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said compound than not administered in combination with said compound; or a dosage of said compound is lower when administered in combination with said antagonist than not administered in combination with said antagonist, or both.

NCBI PubMed National Library of Medicine NLM

PubMed | Nucleotide | Protein | Genome | Structure | PMC | Taxonomy | OMIM | Books

Search PubMed for HP2/4 and alpha4 Preview Go

Clear

Limits | Preview/Index | **History** | Clipboard | Details

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#28	Search **HP2/4 and alpha4**	13:30:04	2
#27	Search **HP2/4 and alpha 4**	13:29:58	0
#25	Search **ellis and barber and 925**	13:20:48	1
#23	Search **hp2/4 antibodies and alpha4**	13:12:19	2
#22	Search **hp2/4 antibodies and alpha 4**	13:12:10	0
#19	Search **p4c2 antibodies and alpha 4**	12:35:28	3
#18	Search **p4c2 antibodies and alpha4**	12:35:25	0
#14	Search **L25 and alpha 4 and antibody**	12:29:55	6
#13	Search **L25 and alpha 4**	12:29:36	11
#9	Search **L25 and alpha4**	12:28:03	3
#8	Search **L25 and myeloma**	12:27:51	0
#7	Search **l25 and myeloma**	12:27:43	0
#5	Search **hp antibodies and alpha4**	12:08:26	2
#4	Search **hp antibodies**	12:08:08	644
#3	Search **hp 1/2 antibodies**	12:07:57	0
#2	Search **hp1/2 antibodies**	12:07:51	0

Clear History